Sugi Predict

Sugi Predict / Compounds / (+/-)-Wiedendiol B

(+/-)-Wiedendiol B

(+/-)-Wiedendiol B

SCHEMBL1229327

COc1ccc(O)c(O)c1/C=C1\[C@@H](C)CC[C@H]2C(C)(C)CCC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CETP P11597 9/20 1.00
▸ PTGS2 P35354 1/20 1.00
▸ PIK3CA P42336 6/20 0.46
▸ PIK3CG P48736 6/20 0.46
▸ TP53 P04637 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+/-)-Wiedendiol B SCHEMBL8275931 1.00 CETP (1.00) CETPPTGS2PIK3CAPIK3CGTP53
SCHEMBL13692584 0.83 CETP (0.70) CETPPTGS2PIK3CAPIK3CGTP53
Siphonodictyal B SCHEMBL30568098 0.74 CETP (0.59) CETPPTGS2PIK3CAPIK3CGUSP2
Siphonodictyal B SCHEMBL23597092 0.74 CETP (0.59) CETPPTGS2PIK3CAPIK3CGUSP2
Siphonodictyal B SCHEMBL23597056 0.74 CETP (0.59) CETPPTGS2PIK3CAPIK3CGUSP2
Siphonodictyal B SCHEMBL23597098 0.74 CETP (0.59) CETPPTGS2PIK3CAPIK3CGUSP2
Siphonodictyal B SCHEMBL25770144 0.74 CETP (0.59) CETPPTGS2PIK3CAPIK3CGUSP2
SCHEMBL23597436 0.71 CETP (0.55) CETPPTGS2PIK3CAPIK3CGALOX15
SCHEMBL23597096 0.71 CETP (0.55) CETPPTGS2PIK3CAPIK3CGALOX15
SCHEMBL31536089 0.69 CETP (0.53) CETPPTGS2PIK3CAPIK3CGTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122146-A1 COMPOUNDS FOR REDUCING NEUROINFLAMMATION THE SCRIPPS RESEARCH INSTITUTE 2025-04-17 — — US claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 — — EP disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
US-20250122146-A1 COMPOUNDS FOR REDUCING NEUROINFLAMMATION THE SCRIPPS RESEARCH INSTITUTE 2025-04-17 — — US disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 — — US disclosed
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels ASCENDIS PHARMA A/S (DE) 2023-01-24 — — US disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 — — EP disclosed
EP-3592393-B1 RELEASABLE CONJUGATES QUIAPEG PHARMACEUTICALS AB (SE) 2021-12-01 — — EP disclosed
WO-2013160340-A1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA A/S (DK) 2013-10-31 — — WO disclosed
WO-2013024048-A1 POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
WO-2013024049-A1 PROTEIN CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
WO-2013024047-A1 HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS ASCENDIS PHARMA A/S (DK) 2013-02-07 — — US disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 — — US disclosed
EP-2459220-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS Ascendis Pharma A/S (DK) 2012-06-06 — — EP disclosed
WO-2011089214-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS ASCENDIS PHARMA AS (DK) 2011-07-28 — — WO disclosed
WO-2011012715-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2011-02-03 — — WO disclosed
WO-2009112622-A1 METHOD FOR THE PREPARATION OF MERO SESQUITERPENES FROM LABDANE DITERPENES UNIVERSIDAD DE GRANADA (ES) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS CTSL, SLC16A7, SLC16A8 CETP 762/4885PTGS2 3444/4885PIK3CA 1671/4885
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 CETP 1284/4885PTGS2 114/4885PIK3CA 2342/4885
US-20250122146-A1 COMPOUNDS FOR REDUCING NEUROINFLAMMATION HSF1, HSPA2, KEAP1 CETP 4053/4885PTGS2 267/4885PIK3CA 3928/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 CETP 1284/4885PTGS2 114/4885PIK3CA 2342/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 CETP 338/4885PTGS2 2908/4885PIK3CA 4443/4885
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels PLG, PHYKPL, PLOD3 CETP 1284/4885PTGS2 114/4885PIK3CA 2342/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 CETP 338/4885PTGS2 2908/4885PIK3CA 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.